Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 6 of 6 descriptions
| No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GABAPENTIN (D00332) | [1] Gabapentin Gabapentin | [1] Gabapentin
Gabapentin
(D00332) 💬1. GABAPENTIN
| [5] CACNA2D1 CACNA2D1,CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 1. GABAPENTIN
| [9] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 [9] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac ... | [5] 6 6, 13, 19, 70, 298 💬
| ||||||||||||||||||||||||||
| 2 | Gabapentin (neurontin® capsule 300mg) treatment (D00332) | [1] Gabapentin Gabapentin | [1] Gabapentin
Gabapentin
(D00332) 💬2. Gabapentin (neurontin® capsule 300mg) treatment
| [5] CACNA2D1 CACNA2D1,CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 2. Gabapentin (neurontin® capsule 300mg) treatment
| [9] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 [9] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac ... | [1] 70 70 💬2. Gabapentin (neurontin® capsule 300mg) treatment
| ||||||||||||||||||||||||||
| 3 | Gabapentin prescriptions (D00332) | [1] Gabapentin Gabapentin | [1] Gabapentin
Gabapentin
(D00332) 💬3. Gabapentin prescriptions
| [5] CACNA2D1 CACNA2D1,CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 3. Gabapentin prescriptions
| [9] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 [9] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac ... | [1] 298 298 💬3. Gabapentin prescriptions
| ||||||||||||||||||||||||||
| 4 | Multi-modal pain management [Acetaminophen + Gabapentin] (D00332) | [2] Acetaminophen Acetaminophen,Gabapentin | [2] Acetaminophen
Acetaminophen
,Gabapentin (D00332) 💬 4. Multi-modal pain management [Acetaminophen + Gabapentin]
| [7] CACNA2D1 CACNA2D1,CACNA2D2, CACNA2D3, CACNA2D4, PTGS1, PTGS2, SLC6A1 💬 4. Multi-modal pain management [Acetaminophen + Gabapentin]
| [31] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alzheimer disease, Arachidonic acid metabolism, Arrhythmogenic right ventricular cardiomyopathy, C-type lectin receptor signaling pathway, Cardiac muscle contraction, Chemical carcinogenesis - DNA adducts, Dilated cardiomyopathy, GABAergic synapse, Human cytomegalovirus infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, MAPK signaling pathway, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, Synaptic vesicle cycle, TNF signaling pathway, VEGF signaling pathway 💬 [31] Adrenergic signaling in cardiomyocytes, Alzheimer disease, Arachidonic acid metabolism, Arrhyth ... | [1] 70 70 💬4. Multi-modal pain management [Acetaminophen + Gabapentin]
| ||||||||||||||||||||||||||
| 5 | Multi-modal pain management [Valium + Gabapentin] (D00332) | [1] Gabapentin Gabapentin | [1] Gabapentin
Gabapentin
(D00332) 💬5. Multi-modal pain management [Valium + Gabapentin]
| [5] CACNA2D1 CACNA2D1,CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 5. Multi-modal pain management [Valium + Gabapentin]
| [9] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 [9] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac ... | [1] 70 70 💬5. Multi-modal pain management [Valium + Gabapentin]
| ||||||||||||||||||||||||||
| 6 | Transdermal fentanyl matrix, gabapentin (D00332) | [2] Fentanyl Fentanyl,Gabapentin | [2] Fentanyl
Fentanyl
,Gabapentin (D00332) 💬 6. Transdermal fentanyl matrix, gabapentin
| [6] CACNA2D1 CACNA2D1,CACNA2D2, CACNA2D3, CACNA2D4, OPRM1, SLC6A1 💬 6. Transdermal fentanyl matrix, gabapentin
| [12] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Estrogen signaling pathway, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 [12] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardia ... | [1] 70 70 💬6. Transdermal fentanyl matrix, gabapentin
|